SAN DIEGO, March 2, 2017 /PRNewswire/ -- OncoSec
Medical Incorporated ("OncoSec") (NASDAQ: ONCS), a company
developing DNA-based intratumoral cancer immunotherapies, announced
today that the Company will host its fiscal second quarter 2017
financial results conference call on Thursday, March 16 at 1:15
PM PST/4:15 PM EST.
To access the audio broadcast, please call (877) 731-1960 and
enter the conference ID number: 74585937. An archived version of
the presentation will be available for 90 days on the
"Investors" section of OncoSec's website:
http://ir.oncosec.com/events-presentations.
About OncoSec Medical Incorporated
OncoSec is a biotechnology company developing DNA-based
intratumoral immunotherapies with an investigational technology,
ImmunoPulse®, for the treatment of cancer.
ImmunoPulse® is designed to enhance the local delivery
and uptake of DNA-based immune-targeting agents, such as IL-12. In
Phase I and II clinical trials, ImmunoPulse® IL-12 has
demonstrated a favorable safety profile and evidence of anti-tumor
activity in the treatment of various solid tumors as well as the
potential to initiate a systemic immune response. OncoSec's lead
program, ImmunoPulse® IL-12, is currently in clinical
development for several indications, including metastatic melanoma,
and triple-negative breast cancer. The program's current focus is
on the significant unmet medical need in patients with melanoma who
are refractory or non-responsive to anti-PD-1/PD-L1 therapies. In
addition to ImmunoPulse® IL-12, the Company is also
identifying and developing new immune-targeting agents for use with
the ImmunoPulse® platform. For more information, please
visit www.oncosec.com.
CONTACT:
Investor Relations
OncoSec Medical Incorporated
855-662-6732
investors@oncosec.com
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/oncosec-to-host-second-quarter-financial-conference-call-on-march-16-2017-300416455.html
SOURCE OncoSec Medical Incorporated